<DOC>
	<DOCNO>NCT01381575</DOCNO>
	<brief_summary>This study design evaluate immunogenicity safety GSK Biologicals ' HPV-16/18 vaccine administer accord alternative 2-dose schedule ( 0,6 month 0,12 month ) healthy 9-14 year old female compare standard 3-dose schedule ( 0,1,6 month ) 15-25 year old female .</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety Two 2-dose Human Papillomavirus ( HPV ) Vaccine Schedules 9-14 Year Old Girls</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol or/ subject investigator believe parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol A female , include , 9 25 year age time first vaccination Written inform consent obtain subject/from parent ( ) /LAR ( ) subject prior enrolment study . In addition , subject legal age consent sign personally date write informed assent form Healthy subject Female subject nonchildbearing potential may enrol study Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire vaccination period two month last study vaccine dose Pregnant breastfeed A female planning become pregnant , likely become pregnant planning discontinue contraceptive precaution entire vaccination period two month last study vaccine dose Previous vaccination HPV plan administration another HPV vaccine study Child care . A child care child place control protection agency , organisation , institution entity court , government government body , act accordance power confer law regulation . The definition child care include child adopt appointed legal guardian . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine Cancer autoimmune disease treatment Planned administration/administration vaccine/product foreseen study protocol within 30 day dose vaccine . Administration routine meningococcal , hepatitis B , hepatitis A , inactivated influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day dose study vaccine allow . Enrolment defer subject outside specify window Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Previous administration MPL AS04 adjuvant . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period Any confirm suspected immunosuppressive immunodeficient condition Family history congenital hereditary immunodeficiency Major congenital defect serious chronic illness Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screening test , opinion investigator precludes administration study vaccine Acute disease and/or fever time enrolment</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HPV infection</keyword>
	<keyword>Human Papillomavirus</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>HPV-16</keyword>
	<keyword>HPV-18</keyword>
	<keyword>vaccine</keyword>
</DOC>